论文部分内容阅读
本院自1989年10月至1993年12月底采用随机分组的方法对90例中晚期食管癌症进行分组：卡铂增敏放疗45例，单纯放疗45例．两组病期、病理、全身情况基本相同．放射治疗均用10MVX线等中心放疗，治疗总剂量为65Gy～70Gy／6～7周，化疗方案；卡铂0.4（第1天），5-氟脲嘧啶（第2天至第6天），休息2～3周重复一次，休息3～4天即放疗，当总量达40Gy时摄片比较，再次化疗后将放疗剂量加至65Gy～70Gy。摄片比较结果：卡铂增敏组CR23例占51％（23／45），单放组CR12例，占27％（12／45）．两组经统计学处理，p＜0.05，呈显著性差异。1年生存率卡铂增敏组56％（25／45）．单放组31％（14／45）．p＜0．05。3年存活率卡铂增敏组42％（15／36），单放组19％（7／36），经统计学处理p＜0．05；呈显著性差异。因此，卡铂增敏放疗对近期疗效较单纯放疗好，值得进一步研究。
In this hospital from October 1989 to the end of December 1993, 90 patients with moderate-advanced esophageal cancer were randomly divided into groups: 45 cases with carboplatin sensitization radiotherapy and 45 cases with radiotherapy alone. The two groups were basically the same in terms of pathology, pathology, and general condition. Radiotherapy uses 10 MV X-rays and other center radiotherapy with a total dose of 65 Gy to 70 Gy/6 to 7 weeks for chemotherapy; carboplatin 0.4 (day 1) and 5-fluorouracil (day 2 to day 6). Take a rest for 2 to 3 weeks, and take a rest for 3 to 4 days. When the total dose reaches 40 Gy, compare the radiographs. After chemotherapy, add the radiotherapy dose to 65 Gy to 70 Gy. Photographic comparison results: Carboplatin sensitized group accounted for 51% of CR (23/45), and single-release group CR12 cases, accounting for 27% (12/45). The two groups were statistically processed, p<0.05, showing a significant difference. 1-year survival rate of carboplatin sensitization group was 56% (25/45). Single play group 31% (14/45). p<0.05 The 3-year survival rate was 42% (15/36) in the carboplatin sensitization group, and 19% (7/36) in the radiotherapy group. Statistical analysis showed a difference of p<0.05. Therefore, carboplatin sensitization radiotherapy is more effective than simple radiotherapy in the near future and deserves further study.